Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"
Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.
A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.
Hot Picks Today
"How Did His Face and Gait Look?"... Kim Jong Un Appears in Plain Sight, Making Death Rumors Look Baseless
- "I Only Buy Domestic Brands, and I Can't Pay Full Price": Chinese Consumers Turn Away From Nike as It Falls Out of Favor
- "Let's Give Unemployment Benefits to Those Who Find Jobs Quickly and Stay Long-Term"... Petition Takes Aim at Compensation for 'Voluntary Resignations'
- "Undervalued at Global Financial Crisis Levels," Samsung Electronics and SK hynix Set for a W-Shaped Rebound - But When? [Weekend Money]
- "Shares Hit Daily Limit on 56 Billion Won News"... Marubeni Launches Tender Offer for K-Beauty Firm of 'Chae Sira's Husband' Kim Taewook
The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
